Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hepatitis B: therapeutic perspectives.

M Rizzetto1, M Lagget

  • 1Dipartimento di Gastroenterologia, Università di Torino, Azienda Ospedaliera S. Giovanni Battista, Torino, Italy.

Forum (Genoa, Italy)
|April 12, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Treatment of hepatitis D: an unmet medical need.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2020
Same author

Letter: HBsAg kinetics-guided interferon therapy for chronic hepatitis D - authors' reply.

Alimentary pharmacology & therapeutics·2017
Same author

HBsAg kinetics in chronic hepatitis D during interferon therapy: on-treatment prediction of response.

Alimentary pharmacology & therapeutics·2016
Same author

Hepatorenal syndrome after treatment of visceral leishmaniasis requiring terlipressin therapy.

Minerva gastroenterologica e dietologica·2015
Same author

Antiviral treatment discontinuation among hepatitis C-infected individuals with thrombocytopenia.

Journal of viral hepatitis·2015
Same author

Letter: renal effects of tenofovir in adefovir dipivoxil-experienced HBV patients.

Alimentary pharmacology & therapeutics·2014
Same journal

The basis of allograft acceptance.

Forum (Genoa, Italy)·2011
Same journal

Recurrent liver disease after liver transplantation.

Forum (Genoa, Italy)·2011
Same journal

Integrated treatments for non-small cell lung cancer.

Forum (Genoa, Italy)·2006
Same journal

Gastrointestinal tumors.

Forum (Genoa, Italy)·2006
Same journal

Primary and metastatic brain tumors.

Forum (Genoa, Italy)·2006
Same journal

Impact of integrated treatments on patient management in solid tumors: from diagnosis to palliative care.

Forum (Genoa, Italy)·2006
See all related articles

Interferon therapy is effective for few chronic hepatitis B (CHB) patients. Lamivudine (LAM) is a promising antiviral, but resistance can emerge, necessitating ongoing treatment for sustained viral suppression.

Area of Science:

  • Hepatology
  • Virology
  • Immunology

Background:

  • Chronic hepatitis B (CHB) therapy with interferon (IFN) shows limited efficacy, particularly in HBeAg-negative cases.
  • Synthetic nucleosides, like lamivudine (LAM), represent a promising antiviral approach for CHB.
  • LAM effectively inhibits HBV replication and reduces inflammation in both HBeAg-positive and HBeAg-negative CHB.

Purpose of the Study:

  • To evaluate the efficacy and limitations of lamivudine (LAM) therapy in chronic hepatitis B (CHB).
  • To assess the impact of LAM on viral suppression and seroconversion in different CHB genotypes.
  • To identify the challenges associated with long-term LAM treatment, including antiviral resistance.

Main Methods:

  • Clinical evaluation of interferon (IFN) therapy in CHB patients.

Related Experiment Videos

  • Assessment of lamivudine (LAM) efficacy in inhibiting HBV replication and inflammation.
  • Monitoring of HBeAg seroconversion rates during LAM therapy.
  • Investigation of LAM resistance mutations in the HBV polymerase gene.

    • Main Results:

    • LAM is well-tolerated and effective in inhibiting HBV in both HBeAg-positive and HBeAg-negative CHB.
    • HBeAg-positive CHB patients achieve anti-HBe seroconversion at a rate increasing to 40% by year three.
    • Continuous LAM therapy is required for viral repression in HBeAg-negative CHB.
    • A significant drawback is the emergence of LAM-resistant HBV mutants, potentially leading to disease relapse.

    Conclusions:

    • Lamivudine (LAM) offers a well-tolerated and effective treatment option for chronic hepatitis B (CHB).
    • Long-term LAM therapy necessitates continuous treatment due to the risk of developing resistant HBV strains.
    • Emerging antiviral drugs like adefovir are being investigated for CHB management.